Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Taysha Gene Therapies Inc (NASDAQ: TSHA) closed at $5.66 in the last session, up 0.18% from day before closing price of $5.65. In other words, the price has increased by $0.18 from its previous closing price. On the day, 1.46 million shares were traded. TSHA stock price reached its highest trading level at $5.69 during the session, while it also had its lowest trading level at $5.59.
Ratios:
We take a closer look at TSHA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.47 and its Current Ratio is at 10.47. In the meantime, Its Debt-to-Equity ratio is 0.32 whereas as Long-Term Debt/Eq ratio is at 0.31.
Upgrades & Downgrades
In the most recent recommendation for this company, Raymond James on October 21, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $13.
On July 11, 2025, BofA Securities started tracking the stock assigning a Buy rating and target price of $8.
On June 27, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $5.BMO Capital Markets initiated its Outperform rating on June 27, 2024, with a $5 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when Nagendran Sukumar sold 260,047 shares for $4.51 per share. The transaction valued at 1,172,812 led to the insider holds 1,006,439 shares of the business.
Nagendran Sukumar sold 110,125 shares of TSHA for $523,094 on Nov 28 ’25. The President and Head of R&D now owns 1,006,439 shares after completing the transaction at $4.75 per share. On Nov 28 ’25, another insider, Nagendran Sukumar, who serves as the Officer of the company, bought 370,172 shares for $4.86 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 1550383488 and an Enterprise Value of 1322122624. For the stock, the TTM Price-to-Sale (P/S) ratio is 245.70 while its Price-to-Book (P/B) ratio in mrq is 7.08. Its current Enterprise Value per Revenue stands at 209.528 whereas that against EBITDA is -13.093.
Stock Price History:
The Beta on a monthly basis for TSHA is 1.01, which has changed by 2.054054 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, TSHA has reached a high of $6.02, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 16.44%, while the 200-Day Moving Average is calculated to be 76.79%.
Shares Statistics:
According to the various share statistics, TSHA traded on average about 6.20M shares per day over the past 3-months and 3705390 shares per day over the past 10 days. A total of 273.92M shares are outstanding, with a floating share count of 223.27M. Insiders hold about 18.49% of the company’s shares, while institutions hold 89.59% stake in the company. Shares short for TSHA as of 1765756800 were 48586771 with a Short Ratio of 7.84, compared to 1763078400 on 48083858. Therefore, it implies a Short% of Shares Outstanding of 48586771 and a Short% of Float of 19.81.
Earnings Estimates
Taysha Gene Therapies Inc (TSHA) is presently subject to a detailed evaluation by 5 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.07 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.24 and -$0.38 for the fiscal current year, implying an average EPS of -$0.34. EPS for the following year is -$0.44, with 5.0 analysts recommending between -$0.29 and -$0.54.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for TSHA’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $4M, resulting in an average revenue estimate of $6.3M. In the same quarter a year ago, actual revenue was $8.33M
